VRTX - Vertex Pharmaceuticals - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92532F1003

Cystic Fibrosis Medications, Pain Relievers, Sickle Cell Disease Treatments

Vertex Pharmaceuticals Incorporated is a biotechnology company that focuses on developing and commercializing life-changing therapies for people with serious diseases. One of their main areas of focus is cystic fibrosis (CF), a genetic disorder that affects the respiratory, digestive, and reproductive systems. They have developed several medications to treat CF, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which are designed to improve lung function and overall health for people with CF.

Vertex is committed to innovation and has a robust pipeline of potential new medicines in various stages of development. For example, VX-522 is a groundbreaking CFTR mRNA therapeutic that aims to treat the underlying cause of CF, and is currently in Phase 1 clinical trial. They are also working on VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain, which is in Phase 3 clinical trial. Additionally, they are developing Exa-cel, a potential treatment for sickle cell disease and transfusion-dependent beta thalassemia, which is in Phase 2/3 clinical trial.

The company's pipeline also includes potential treatments for other serious diseases, such as APOL1-mediated focal segmental glomerulosclerosis, Type 1 Diabetes, and various types of cancer. They are working on several collaborations with other companies, including CRISPR Therapeutics AG, Moderna, Inc., and others, to develop novel therapies for diseases such as Duchenne muscular dystrophy.

Vertex sells its products to specialty pharmacies, hospitals, and clinics in the United States, and has a strong online presence through its website. The company was founded in 1989 and is headquartered in Boston, Massachusetts, with a mission to transform the lives of people with serious diseases.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for VRTX - Vertex Pharmaceuticals  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for VRTX - Vertex Pharmaceuticals  - Stock & Dividends

VRTX Stock Overview

Market Cap in USD 125,411m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1991-07-24

VRTX Stock Ratings

Growth 5y 75.6
Fundamental 62.0
Dividend -
Rel. Performance vs Sector 0.29
Analysts 3.94/5
Fair Price Momentum 517.15 USD
Fair Price DCF 355.44 USD

VRTX Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

VRTX Growth Ratios

Growth 12m 38.56%
Growth Correlation 12m 63%
Growth Correlation 3m 75%
CAGR 5y 22.55%
CAGR/Mean DD 5y 1.84
Sharpe Ratio 12m 1.42
Alpha vs SP500 12m 19.88
Beta vs SP500 5y weekly 0.63
ValueRay RSI 77.05
Volatility GJR Garch 1y 21.92%
Price / SMA 50 6.9%
Price / SMA 200 19%
Current Volume 837.3k
Average Volume 20d 1171.4k

External Links for VRTX Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of VRTX stocks?
As of July 14, 2024, the stock is trading at USD 488.74 with a total of 837,320 shares traded.
Over the past week, the price has changed by +2.99%, over one month by +2.72%, over three months by +23.25% and over the past year by +36.53%.
What are the forecast for VRTX stock price target?
According to ValueRays Forecast Model, VRTX Vertex Pharmaceuticals will be worth about 570.5 in July 2025. The stock is currently trading at 488.74. This means that the stock has a potential upside of +16.72%.
Issuer Forecast Upside
Wallstreet Target Price 473.6 -3.10
Analysts Target Price 388.7 -20.5
ValueRay Target Price 570.5 16.7

Vertex Pharmaceuticals Inc: A Comprehensive Overview

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), founded in 1989, has grown into a leading global biotechnology firm committed to creating transformative medicines for people with serious diseases.

The Heart of Vertex: Cystic Fibrosis

The core focus of Vertex's research and development efforts has been on Cystic Fibrosis (CF), a critical genetic disorder that affects the lungs and digestive system. Pioneering in this field, Vertex has successfully brought to market several treatments that address the underlying cause of CF rather than its symptoms, significantly improving patients' quality of life.

Expanding the Portfolio: Beyond Cystic Fibrosis

While maintaining cystic fibrosis at its core, Vertex has not rested on its laurels. The company has gradually diversified its research portfolio to include other serious diseases. This includes research into pain, infectious diseases, and cancer, amongst others. These endeavors underscore Vertex's commitment to broadening its impact on healthcare by exploring new therapeutic areas.

Current Market Status

As of 2023, Vertex Pharmaceuticals remains a strong player in the biotech industry, thanks to its robust portfolio of CF treatments and burgeoning research into other therapeutic areas. The company has consistently demonstrated financial growth and resilience, partly due to its strategic investments in research and development. Vertex's presence in the market underscores its dedication not only to shareholder value but also to a future where more patients can benefit from innovative therapies.

For more details on the innovative work and the latest news from Vertex Pharmaceuticals, visit their official website here.